Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
V. Welk (Munich, Germany), T. Meul (Munich, Germany), C. Lukas (Munich, Germany), D. Bölükbas (Lund, Sweden), I. Koch (Gauting, Germany), M. Lindner (Gauting, Germany), S. Meiners (Munich, Germany). Analyzing the role of proteasome activator 200 (PA200) in lung cancer. 2849

Member's Comments

No comment yet.

Related content which might interest you: PP138 – Regulation of PA200 in lung cancer Source: ERS Lung Science Conference 2021 Year: 2021 Regulation of PA200 in lung cancer Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 PAK interacting exchange factor (BPIX-a) overexpression in human lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008 Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 TGF-beta-dependent inhibitor of DNA protein (Id) expression in lung fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 521s Year: 2006 Caspase recruitment domain containing protein 9 suppresses non-small cell lung cancer proliferation and invasion via inhibiting MAPK/p38 pathway Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer Source: Annual Congress 2003 - Lung cancer biology Year: 2003 LSC 2012 abstract – Effects of the Hedgehog (Hh) pathway inhibitor GDC-0449 on lung cancer cells and cisplatin resistant lung cancer cells are mediated by lung cancer stem cells (SPs) Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012 Overexpression of inhibitor of DNA-binding proteins and angiogenic markers have higher impact on survival of non small cell lung cancer patients Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Expression of the ILK-PINCH-PARVIN (IPP) complex and its binding partner Rsu-1 in human non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 CDCA promotes non-small-cell lung cancer (NSCLC) migration by regulating Akt/Erk1/2 signaling pathways Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 Long-term proteasome inhibition promotes chemical lung carcinogenesis Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA molecules Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005